文献速递流行病学与生物统计临床试验与 GCP

随机试验的获益与危害结果个性化程度如何:一项系统综述

How personalized are benefit and harm results of randomized trials? A systematic review.
PubMed 文献 · J Clin Epidemiol · 2020-06-09

该系统综述评估2012至2017年发表的高关注度药物干预随机对照试验中获益与危害报告的个性化程度。在296项试验中,仅3%报告了获益-危害复合终点,1%报告了该终点的亚组分析,56.4%报告了获益终点的亚组分析,6.1%报告了危害终点的亚组分析,亚组分析总体质量较差。

要点

  • 高关注度药物RCT中,仅3%报告获益-危害复合终点,个性化报告罕见。
  • 获益和危害终点的亚组分析报告率分别为56.4%和6.1%,复合终点亚组分析仅1%。
  • 亚组分析总体质量较差,仅1项研究报告了临床预测指南。

核心结论

  • 尽管对治疗个性化兴趣浓厚,但高关注度试验中很少报告获益与危害的个性化结果。

研究设计与样本

  • 系统综述纳入2012至2017年发表、至少评估一种药物疗法且被某顶级学术文献摘要服务列为高关注度的随机对照试验,共296项。

主要发现

  • 296项试验中,9项(3%)报告了获益-危害复合终点。
  • 3项(1%)报告了获益-危害复合终点的亚组分析,167项(56.4%)报告了获益终点的亚组分析,18项(6.1%)报告了危害终点的亚组分析。
  • 亚组分析总体质量较差,仅1项研究报告了针对某一结局的临床预测指南。

关键数值与推荐

  • 采用修改版既往发表的 credibility 标准评估亚组分析质量。

临床怎么用

  • 临床解读高关注度药物RCT时,需注意获益与危害的个性化证据(如亚组分析、临床预测指南)报告率低且质量不佳。

局限性

  • 缺乏严谨且广泛接受的个性化报告方法可能是主要障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to review the degree of personalization of benefit and harm in the reporting of recent high-profile randomized controlled trials (RCTs) involving pharmacological interventions. STUDY DESIGN AND SETTING: This study is a systematic review of RCTs published between 2012 and 2017 with at least one intervention evaluating drug therapy and meeting the "high-profile" threshold in a premier academic literature abstraction service. Our primary outcome was the proportion of trials reporting subgroup analyses of a combined benefit-harm outcome. Secondary outcomes included the proportion of trials reporting subgroup analyses or clinical prediction guide for benefits or harms. We assessed the quality of the subgroup analyses using a modified version of previously published credibility criteria. RESULTS: Of 296 eligible RCTs, nine studies (3%) reported a combined benefit-harm endpoint. We found subgroup analyses of a combined benefit-harm endpoint in three studies (1%), a benefit endpoint in 167 studies (56.4%), and a harm endpoint in 18 studies (6.1%). The overall quality of the subgroup analyses was poor. Only one study reported a clinical prediction guide for an outcome. CONCLUSION: Despite great interest in the personalization of therapies, it is rarely reported in high-profile trials. Lack of rigorous and widely accepted methods may be the major barrier.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Yu A, Jeyakumar Y, Wang M, et al. How personalized are benefit and harm results of randomized trials? A systematic review. J Clin Epidemiol. 2020. PMID: 32531265. doi:10.1016/j.jclinepi.2020.05.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。